Back to search

Article

Comparison of the Efficacy of Enfortumab Vedotin between patients with Metastatic Urothelial Carcinoma who were treated with Avelumab or Pembrolizumab: Real-World Data from a Multi-Institutional Study in Japan

2024-02-14

Abstract excerpt

<h4>Objectives: </h4> Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for metastatic urothelial carcinoma (UC) refractory to prior treatment with immune checkpoint inhibitors (ICIs). However, the difference in efficacy of EV after each ICIs and prognostic factors are not well known. We aimed to compare the efficacy of EV in patients with metastatic UC who were treated with avelumab or pembroliz...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
eaea4ad1-bec8-59a0-91b4-5a678c7b4013
DOI
10.21203/rs.3.rs-3952729/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparison of the Efficacy of Enfortumab Vedotin between patients with Metastatic Urothelial Carcinoma who were treated with Avelumab or Pembrolizumab: Real-World Data from a Multi-Institutional Study in JapanDOI 10.21203/rs.3.rs-3952729/v1
Severe Diffuse Ulcerative Esophagitis Following Enfortumab Vedotin and Pembrolizumab in Metastatic Urothelial Carcinoma: A Case ReportSemantic proximity
Histological variant-specific significance of lymph node metastasis for the prognosis of metastatic urothelial carcinoma treated with pembrolizumab: A retrospective multicentric study (YUSHIMA study-04)Semantic proximity
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy.Semantic proximity
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Semantic proximity
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.Semantic proximity
Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin ResistanceSemantic proximity
Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer.Semantic proximity
VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study.Semantic proximity
CAR T cells targeting Nectin-4 safely overcome resistance to anti-Nectin-4 antibody-drug conjugate in solid tumorsSemantic proximity
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.Semantic proximity
Successful Treatment of Metastatic Upper Tract Urothelial Carcinoma With Vemurafenib: Case Report.Semantic proximity
CAR T cells targeting Nectin-4 safely overcome resistance to anti-Nectin-4 antibody-drug conjugate in solid tumorsSemantic proximity
Select a neighboring publication to make it the new centre.